Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v60,p1055)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morgenstern, L.B.
Right arrow Articles by Horwitz, R.I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morgenstern, L.B.
Right arrow Articles by Horwitz, R.I.

Neurology 2003;60:132-135
© 2003 American Academy of Neurology
Brief Communications

Use of Ephedra-containing products and risk for hemorrhagic stroke

L.B. Morgenstern, MD, C.M. Viscoli, PhD, W.N. Kernan, MD, L.M. Brass, MD, J.P. Broderick, MD, E. Feldmann, MD, J.L. Wilterdink, MD, T. Brott, MD and R.I. Horwitz

From the Stroke Program, Department of Neurology, University of Texas at Houston, and Stroke Program (Dr. Morgenstern), University of Michigan Health System, Ann Arbor; Departments of Internal Medicine (Drs. Viscoli and Kernan, and R.I. Horwitz), Neurology (Dr. Brass), and Epidemiology and Public Health (Dr. Brass and R.I. Horwitz), Yale University School of Medicine, New Haven, CT; Department of Neurology (Dr. Broderick), University of Cincinnati, OH; Department of Neurology (Dr. Feldmann and Wilterdink), Brown University School of Medicine, Providence, RI; and Department of Neurology (Dr. Brott), Mayo Clinic, Jacksonville, FL.

Address correspondence and reprint requests to Dr. Lewis B. Morgenstern, Stroke Program, Department of Neurology, University of Michigan Health System, TC 1920/0316, Ann Arbor, MI 48109; e-mail: lmorgens{at}umich.edu

This case-control study examined the association between Ephedra use and risk for hemorrhagic stroke. For use of Ephedra at any dose during the 3 days before the stroke, the adjusted OR was 1.00 (95% CI 0.32 to 3.11). For daily doses of <=32 mg/day, the OR was 0.13 (95% CI 0.01 to 1.54), and for >32 mg/day, the OR was 3.59 (95% CI 0.70 to 18.35). Ephedra is not associated with increased risk for hemorrhagic stroke, except possibly at higher doses.




This article has been cited by other articles:


Home page
 Am J EpidemiolHome page
J. Hallas, L. Bjerrum, H. Stovring, and M. Andersen
Use of a Prescribed Ephedrine/Caffeine Combination and the Risk of Serious Cardiovascular Events: A Registry-based Case-Crossover Study
Am. J. Epidemiol., October 15, 2008; 168(8): 966 - 973.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
E. S. Roach, M. R. Golomb, R. Adams, J. Biller, S. Daniels, G. deVeber, D. Ferriero, B. V. Jones, F. J. Kirkham, R. M. Scott, et al.
Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Stroke, September 1, 2008; 39(9): 2644 - 2691.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
A. N. Westover, S. McBride, and R. W. Haley
Stroke in Young Adults Who Abuse Amphetamines or Cocaine: A Population-Based Study of Hospitalized Patients
Arch Gen Psychiatry, April 1, 2007; 64(4): 495 - 502.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
A. A. Grippo, B. Hamilton, R. Hannigan, and B. J. Gurley
Metal content of ephedra-containing dietary supplements and select botanicals
Am. J. Health Syst. Pharm., April 1, 2006; 63(7): 635 - 644.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
C. E. Dennehy, C. Tsourounis, and A. J. Horn
Dietary supplement-related adverse events reported to the California Poison Control System
Am. J. Health Syst. Pharm., July 15, 2005; 62(14): 1476 - 1482.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
S. C. Smolinske
Herbal Product Contamination and Toxicity
Journal of Pharmacy Practice, June 1, 2005; 18(3): 188 - 208.
[Abstract] [PDF]

Home page
 NeurologyHome page
S. B. Karch, W.N. Kernan, L.M. Brass, C.M. Viscoli, J. P. Broderick, T. Brott, E. Feldmann, J.L. Wilterdink, and L.M. Morgenstern
Use of Ephedra-containing products and risk for hemorrhagic stroke
Neurology, September 9, 2003; 61(5): 724 - 725.
[Full Text] [PDF]

Home page
 NeurologyHome page
J. I. Sirven, J. F. Drazkowski, R. S. Zimmerman, J. J. Bortz, D. L. Shulman, and M. Macleish
Complementary/alternative medicine for epilepsy in Arizona
Neurology, August 26, 2003; 61(4): 576 - 577.
[Full Text] [PDF]

Home page
 JAMAHome page
P. G. Shekelle, M. L. Hardy, S. C. Morton, M. Maglione, W. A. Mojica, M. J. Suttorp, S. L. Rhodes, L. Jungvig, and J. Gagne
Efficacy and Safety of Ephedra and Ephedrine for Weight Loss and Athletic Performance: A Meta-analysis
JAMA, March 26, 2003; 289(12): 1537 - 1545.
[Abstract] [Full Text] [PDF]

Correspondence:

Read all Correspondence

Use of Ephedra-containing products and risk for hemorrhagic stroke
Steven B Karch
Neurology Online, 7 Mar 2003 [Full text]
Reply to Letter to the Editor
Walter N. Kernan, et al.
Neurology Online, 7 Mar 2003 [Full text]